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INTRODUCTION
A great number of  arylnaphthalene lignans have been 
isolated from different species of  Justicia , many of  
them exhibiting diverse biological activities including 
antitumoral[1-4], antiviral[5-7], insecticidal[8], cardiotonic[9,10], 
antiulcerogenic[11] and anti-inflammatory properties[12,13], 
and an ability to inhibit lipid peroxidation[14]. Interesting 
activities also include platelet activating factor antagonism 
and central nervous system action[15]. Recently it has been 
observed that magnolol and honokinol, two neolignans, 
obtained from Magnolia offi cinalis Rehd. et Wils, inhibited 
the contractility of  isolated gastric fundus strips from 
rats treated with Ach or 5-HT and of  isolated ileum 
from guinea pigs treated with Ach or CaCl2; in each case, 
the neolignans behaved as non-competitive muscarinic 
antagonists[16]. However, clinical or experimental studies 
on the effects of  the gastrointestinal activity of  lignans 
obtained from Justicia species have not, to our knowledge, 
been performed.
In a previous paper[17] we reported the isolation from 
Justicia hyssopifolia L. of  an arylnaphthalene lignan and its 
aglycone, now called elenoside and elenin respectively, the 
former being a β-D-glucoside. Elenoside is a cytotoxic 
arylnapthalene lignan (NSC 644013-W/1) that displayed 
cytotoxic activity in the human tumor cell line panel of  
the US National Cancer Institute[18]. Preliminary screening 
results suggest that elenoside exerts a sedative, hypnotic 
barbiturate-type effect[18,19]. In addition, we have found 
that elenoside has digitalis-like activity similar to that of  
mammalian lignans[20]. Recently we have also observed 
that elenoside has central sedative effects and a possible 
application in anxiety conditions[21]. The current study 
was designed to investigate the effects of  elenoside on 
gastrointestinal motility. 
MATERIALS AND METHODS
Plant material and chemicals
Justicia hyssopifolia L. belongs to the family Acanthaceae and 
is an endemic species in the Canary Islands. Leaves of  J. 
hyssopifolia were collected in April 2002 at Punta Cangrejo, 
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Abstract
AIM: To study the effects of elenoside, an arylnaph-
thalene lignan from Justicia hyssopifolia , on gastro-
intestinal motility in vivo  and in vitro  in rats.
METHODS: Routine in vivo  experimental assessments 
were catharsis index, water percentage of boluses, 
intestinal transit, and codeine antagonism. The groups 
included were vehicle control (propylene glycol-ethanol-
plant oil-tween 80), elenoside (i.p. 25 and 50 mg/kg), 
cisapride (i.p. 10 mg/kg), and codeine phosphate 
(intragastric route, 50 mg/kg). In vitro  approaches used 
isolated rat intestinal tissues (duodenum, jejunum, and 
ileum). The effects of elenoside at concentrations of 3.2 
x 10-4, 6.4 x 10-4 and 1.2 x 10-3 mol/L, and cisapride at 
10-6 mol/L were investigated.
RESULTS: Elenoside in vivo  produced an increase in 
the catharsis index and water percentage of boluses and 
in the percentage of distance traveled by a suspension 
of activated charcoal. Codeine phosphate antagonized 
the effect of 25 mg/kg of elenoside. In vitro , elenoside 
in duodenum, jejunum and ileum produced an initial 
decrease in the contraction force followed by an increase. 
Elenoside resulted in decreased intestinal frequency in 
duodenum, jejunum, and ileum. The in vitro  and in vivo  
effects of elenoside were similar to those produced by 
cisapride.
CONCLUSION: Elenoside is a lignan with an action 
similar to that of purgative and prokinetics drugs. 
Elenoside, could be an alternative to cisapride in treatment 
of gastrointestinal diseases as well as a preventive therapy 
for the undesirable gastrointestinal effects produced by 
opioids used for mild to moderate pain.
© 2006 The WJG Press. All rights reserved.
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Adeje, Tenerife. A voucher specimen was deposited at 
the Herbarium of  the Department of  Botany, Faculty 
of  Biology, University of  La Laguna (TFC-28938). 
The elenoside was extracted and identified in Centro de 
Productos Naturales y Agrobiologia, CSIC, of  Tenerife. It was 
suspended in a mixture of  propylene glycol-ethanol-plant 
oil-Tween80 (40:10:50:2) and administered intraperitoneally 
in a total volume of  0.5 mL. The control group received 
vehicle only. An activated charcoal suspension indicator 
was prepared with 10 g activated charcoal (Panreac, 
Barcelona, Spain) and 2.5 g Arabic gum dissolved in 
100 mL of  distilled water. Cisapride was also used 
(Janssen-Cilag, S.A. Madrid, Spain).
Animals and treatment
Male Sprague Dawley rats weighing 200-250 g were 
used. The rats were housed under normal laboratory 
conditions at 22℃ on a standard light-dark schedule (12:12; 
lighted from 8 am-8 pm) and had free access to standard 
laboratory chow and water. Animal care complied with 
the Guide for the Care and Use of  Laboratory Animals 
in accordance with the Guiding Principles in the Use 
of  Animals in Pharmacology. The study protocol was 
approved by the Local Ethical Committee for animal 
experimentation at the University of  La Laguna. 
The standard dosage treatment protocol for each set 
of  experiments described is as follows: rats assigned to 
randomized groups of  10 each receiving intraperitoneally 
(i.p.) a solution of  propylene glycol-ethanol-plant oil-
Tween 80 (40:10:50:2) (vehicle control group), 25 or 50 
mg/kg of  elenoside in vehicle, or 10 mg/kg cisapride.
Catharsis index
The established index of  catharsis is the number of  humid 
boluses produced in 24 h. Masri et al found that the majority 
of  humid boluses are produced in the fi rst hours following 
administration of  the substance[22]. Thus, we used their 
method to study the effect of  elenoside. Rats were fasted 
for 24 h prior to the experiment. Following this period, the 
rats received the standard dosage treatment protocol (n = 
10 per dosage group). Rats were then individually placed in 
metabolism cages, and the boluses were collected for a 6 h 
period above blotting paper to facilitate counting. 
Water percentage of boluses
Using the standard dosage protocol described above, we 
tested the water percentage of  the boluses. Rats (n = 10 
per dosage group) were individually placed in metabolism 
cages, and the boluses were collected in a methacrylate 
container for a period of  6 h and deposited in a watch 
glass. Afterward, the samples were weighed and placed in 
a heater at 100℃ for 3 h, followed by another weighing to 
establish the percentage of  water in each. 
Intestinal transit 
This experimental method allows the evaluation of  drug 
action on intestinal transit speed, by measuring the dis-
tance travelled by a suspension of  activated charcoal when 
it has been administered intragastrically (po). Rats (n = 10 
per dosage group) were fasted for 24 h prior to the experi-
ment. At 15 min following treatment with the standard 
dosage protocol, the rats received 2 mL of  a suspension 
of  activated charcoal po. After 20 min, the rats were anes-
thetized and sacrifi ced; their intestines were removed from 
the pylorus through the ileocecal junction. The migration 
of  activated charcoal from the pylorus to the most distal 
point of  migration was expressed as distance (cm) migra-
tion using the stain. The percentage of  distance travelled 
by the activated charcoal suspension established the intes-
tinal transit. This percentage was expressed as % = 100 × 
l/L, in which “l” is the migration distance of  the activated 
charcoal and “L” is the distance between the pylorus and 
the ileocecal junction. 
Intestinal transit and codeine antagonism
Using the standard treatment protocol, we studied the 
effect of  elenoside in the presence of  codeine phosphate, 
an opioid with inhibitory activity on intestinal motility. 
Following administration of  the standard dosage treatment, 
the rats immediately received 50 mg/kg of  codeine 
phosphate po. The method used for the measurement 
of  intestinal transit was the same as that described in the 
preceding section.
Isolated rat intestine
Rats were anesthetized and sacrificed. The abdomen 
was opened and a length of  duodenum, jejunum and 
ileum was removed and placed in Tyrode´s solution. 
Pieces of  smooth muscle (1-2 cm) were dissected free 
from surrounding tissues and mounted in an organ 
bath with Tyrode´s solution at 37℃, pH 7.4, through 
which a mixture of  50 mL/L CO2 and 950 mL/L O2 
bubbled continuously[23]. The isotonic contractions 
of  the preparation were recorded on a Grass Model 
7D Polygraph through a Statham force displacement 
transducer. The load applied to the lever was 1 g. After 
stabilization, the effect of  elenoside was studied for 5 min 
at the following concentrations: 3.2 × 10-4, 6.4 × 10-4 and 
1.2 × 10-3 mol/L, and cisapride at 10-6 mol/L. Ten samples 
each of  duodenum, jejunum, and ileum were used for each 
concentration.
Statistical analysis
Statistical analysis was performed using the Prism program 
with two-way analysis of  variance (ANOVA) (between 
group-factor: dose repeated measures factor: time), 
followed by Tukey´s Multiple Comparison post-hoc test. 
For nonparametric analysis, the Kruskal-Wallis test, was 
followed by the Mann-Whitney test for catharsis index, 
water of  boluses, intestinal transit, and intestinal transit 
and codeine antagonism. A probability of  5% or less was 
considered to indicate a signifi cant difference.
RESULTS
Catharsis index 
Table 1 shows the results of  cathartic activity for the 
vehicle control group and groups receiving elenoside at 
doses of  25 or 50 mg/kg or cisapride at dose of  10 mg/
kg. Elenoside produced an increase in the catharsis index 
compared to the control group. The results of  50 mg/kg 
group and controls (P < 0.01) and of  the 50 mg/kg and 25 
www.wjgnet.com
7144      ISSN 1007-9327     CN 14-1219/R     World J Gastroenterol      November 28, 2006    Volume 12    Number 44
mg/kg elenoside treatments, respectively, were signifi cantly 
different from one another. Cisapride produced an increase 
in the catharsis index compared to the control group (P < 
0.05), but it did not differ signifi cantly from 50 mg/kg of  
elenoside in its effects.
Water percentage of boluses 
Figure 1 shows the results of  the water percentage of  
boluses analysis for control group, elenoside at doses 
of  25 and 50 mg/kg, and cisapride at 10 mg/kg. Both 
concentrations of  elenoside produced an increase in water 
percentage vs vehicle control (vs 25 mg/kg elenoside, P < 
0.01; vs 50 mg/kg elenoside, P < 0.01). Cisapride caused 
a significant increase in the water percentage versus the 
control group (P < 0.01), an effect similar to that produced 
by 50 mg/kg elenoside. 
Intestinal transit 
Figure 2 shows the results of  the analysis of  the effects 
of  elenoside and cisapride on small intestinal transit (SIT) 
speed. Both concentrations of  elenoside produced an 
increase in the percentage of  distance the suspension of  
activated charcoal travelled vs the vehicle control (vs 25 
mg/kg elenoside, P < 0.01; vs 50 mg/kg elenoside, P < 0.01). 
Cisapride produced a significant increase in SIT (control 
vs cisapride 10 mg/kg, P < 0.05). There was no difference 
between cisapride and the 50 mg/kg of  elenoside.
Intestinal transit and codeine antagonism 
Figure 3 shows the results of  SIT analysis for elenoside 
with codeine phosphate. Codeine phosphate antagonized 
the effect of  25 mg/kg of  elenoside. Moreover, codeine 
phosphate at 50 mg/kg produced an antagonistic effect on 
50 mg/kg of  elenoside and 10 mg/kg of  cisapride, although 
this effect was not complete (control vs 50 mg/kg elenoside, 
P < 0.05; control vs 10 mg/kg cisapride, P < 0.05) 
Isolated rat intestine 
Figure 4 A-C show the results of  the concentration force 
analysis; effects of  elenoside and cisapride on duodenum, 
jejunum and ileum are depicted in Figures 4A, 4B and 4C, 
respectively. There was a clear dose-effect relationship over 
the three concentrations of  elenoside.
At one minute, elenoside produced a decrease in 
the contraction force, which continued with increasing 
concentration from 3.2 × 10-4 mol/L (P < 0.01) to 6.4 
× 10-4 mol/L (P < 0.01) to 1.2 × 10-3 mol/L (P < 0.01) 
during a five-minute assessment. Cisapride produced an 
effect similar to that of  the 6.4 × 10-4 mol/L of  elenoside. 
Elenoside at a concentration of  1.2 × 10-3 mol/L produced 
a significant increase in contraction force vs 3.2 × 10-4 
mol/L at 2 (P < 0.01), 4 (P < 0.01) and 5 (P < 0.01) min 
respectively (Figure 4A).
Elenoside applied to jejunum produced a decrease 
in the contraction force at one minute, followed by an 
Table 1  Effect of vehicle control, elenoside (E) and cisapride 
(C) on catharsis index in rats (n  = 10) per treatment group
Rat weight Catharsis index
Control 239 ± 4 0.1
E-25 mg/kg 240 ± 3 1.5
E-50 mg/kg 238 ± 3 2.16a
C-10 mg/kg 236 ± 2 2.04a
Values are mean ± SE for 10 rats. aP < 0.05 vs control.
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Figure 1  Percentage increase in water of boluses in vehicle control, elenoside, 
and cisapride. Values are mean ± SE for 10 rats/group. aP < 0.05 vs control.
Figure 2  Small intestinal transit (SIT) in vehicle control and elenoside-treated  and 
cisapride-treated animals. Values are mean ± SE for 10 rats/group. aP < 0.05 vs 
control.
Figure 3  Codeine phosphate induced delay in small intestinal transit (SIT) in 
vehicle control, elenoside, and cisapride groups. Values are mean ± SE for 10 
rats/group. aP < 0.05 vs control.
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increase at concentrations of  3.2 × 10-4 mol/L (P < 0.01), 
6.4 × 10-4 mol/L (P < 0.05), and 1.2 × 10-3 mol/L (P < 
0.01) at 5 min. Cisapride produced an effect similar to that 
obtained with elenoside at a concentration of  3.2 × 10-4 
mmol/L (Figure 4B).
When elenoside was applied to ileum, a decrease in the 
contraction force was produced a minute later. In the next 
minute, the contraction force increased and continued to 
do so up to fi ve minutes with elenoside concentrations of  
6.4 × 10-4 mol/L (P < 0.01) and 1.2 × 10-3 mol/L (P < 0.01). 
There was no effect on contraction force with the mid-
range concentration of  elenoside. Cisapride induced an 
effect similar to that of  elenoside at a concentration of  1.2 
× 10-3 mol/L. Elenoside at a concentration of  3.2 × 10-4 
mol/L produced a signifi cant increase in the contraction 
force vs 1.2 × 10-3 mol/L elenoside at 3 (P < 0.05) and 4 (P 
< 0.05) min, respectively (Figure 4C).
Figure 5A-C depicts results from the time-course 
analysis of  the effects of  elenoside on intestinal frequency 
of  duodenum, jejunum, and ileum respectively. Elenoside 
produced a decrease in the intestinal frequency of  
duodenum at concentrations of  6.4 × 10-4 mo/L (P < 0.05) 
and 1.2 × 10-3 mo/L (P < 0.01) during the time-course. 
Cisapride produced an effect similar to that of  elenoside 
at a concentration of  1.2 × 10-3 mo/L. Elenoside at a 
concentration of  1.2 × 10-3 mo/L produced a signifi cant 
decrease in the intestinal frequency vs 3.2 × 10-4 mo/L at 3 (P 
< 0.01) and 4 (P < 0.01) min, respectively (Figure 5A).
Elenoside decreased intestinal frequency in jejunum 
at all concentrations used during the time-course. No 
statistical differences among the concentrations of  
elenoside were observed (Figure 5B).
Elenoside produced a decrease in intestinal frequency 
in ileum at all concentrations, but only the concentration 
of  1.2 × 10-3 mo/L (P < 0.01) produced a statistically 
signifi cant decrease (Figure 5C). 
DISCUSSION
In this study, elenoside, has been shown to act as a 
stimulant of  gastrointestinal motility. It produced an 
increase in the catharsis index and in the number of  humid 
boluses at a dose of  50 mg/kg. The water volume of  the 
boluses was also enhanced after treatment with elenoside 
at the two doses used. These effects of  elenoside on the 
gastrointestinal tract suggest its actions similar to that of  
purgative drugs.
Another effect of  elenoside was the increase in the 
distance traveled by the charcoal suspension at doses of  
25 and 50 mg/kg. The distance traveled by the charcoal 
suspension has been used in the evaluation of  drugs to 
determine their effects on gastrointestinal motility[24-26]. 
Elenoside elicited gastrointestinal activity similar to 
that effected by cisapride at a dose of  10 mg/kg. This 
effect exerted by elenoside suggested an action similar 
to that of  cisapride, a commonly used prokinetic drug 
C
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Figure 4  A: Time-course of the effects of elenoside and cisapride on contraction force in rat duodenum vs baseline. Values are mean ± SE for 10 duodenum samples dur-
ing 6 min; aP < 0.05. B: Time-course of the effects of elenoside and cisapride on contraction force in rat jejunum vs baseline. Values are mean ± SE for 10 jejunum samples 
during 6 min; aP < 0.05. C: Time-course of the effects of elenoside and cisapride on contraction force in rat ileum vs baseline. Values are mean ± SE for 10 ileum samples 
during 6 min; aP < 0.05.
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Figure 5  A: Time-course of the effects of elenoside and cisapride on intestinal frequency in the rat duodenum vs baseline. Values are mean ± SE for 10 duodenum sam-
ples during 6 min; aP < 0.05. B: Time-course of the effects of  elenoside and cisapride on intestinal frequency in the rat jejunum vs baseline. Values are mean ± SE for 10 
jejunum samples during 6 min; aP < 0.05. C: Time-course of the effects of elenoside and cisapride on intestinal frequency in the rat ileum vs baseline. Values are mean ± 
SE for 10 ileum samples during 6 min; aP < 0.05.
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that acts via a mechanism that facilitates cholinergic 
neurotransmission[27], and of  other prokinetic drugs, 
such as metoclopramide, domperidone, erythromycin, 
and mosapride[28,29], ghrelin and GHRP-6[30], betanecol[31], 
and magnolol and honokiol[16]. Other lignans can exert 
similar effects: Podophyllotoxin and picropodophyllotoxin, 
lignans isolated from Podophyllum species, and produce 
diarrhea when administered to animals[32]. Herbal remedies 
with prokinetic activity similar to elenoside are peppermint 
oil[33], Cocculus hirsutus[34], Zingiber officinale[35], Indigofera 
dendroides[25], Shundao granules[36], and Banxia-houpo-tang 
HKT[37].
Codeine phosphate totally antagonized this prokinetic 
action at the lowest dose of  elenoside and partially 
antagonized it at the higher elenoside dose. In addition, it 
antagonized the prokinetic action of  cisapride. Codeine 
phosphate is an opium alkaloid with an activity similar to 
but weaker than that of  morphine. It is given mainly orally 
in the treatment of  mild to moderate pain[38]. However, 
although opioids are given to relieve pain, they exert 
undesirable gastrointestinal side effects such as nausea, 
vomiting, and a decreased gastrointestinal transit[39]. 
Elenoside could be an alternative together with 
cisapride in the treatment of  the undesirable gastrointes-
tinal effects produced by opioid drugs. Increased peristaltic 
and cathartic activity are parameters of  irritant cathartics, 
according to Fling classifi cation[40]. 
 In isolated rat duodenum, jejunum, and ileum, elenoside 
produced a decrease in the contraction force followed by 
an increase. Elenoside applied to duodenum and ileum 
decreased intestinal frequency, but no significant changes 
in jejunum were found. Other lignans have been shown 
to affect contraction force and intestinal frequency[41-43]. 
Lignans obtained from Podophylum species caused a decrease 
in the initial rate and amplitude of  contractions of  isolated 
intestinal preparations followed by an increase in the force 
of  contraction[32]. 2, 3-dibenzil-butirolactone, a lignan 
obtained from Carthamus tinctorus L. (Compositae), was 
responsible for the cathartic activity of  this plant[44]. Curcuma 
longa relaxed spontaneous contractions in isolated rabbit 
jejunum[45]. On the other hand, some lignans used in the 
treatment of  diarrhea, produced an inhibition in the normal 
intestine propellant movement[46]. Magnolol and honokiol 
obtained from M. offi cinalis induced a decrease in contractility 
of  guinea pig ileum[16]. 
Traditional herbal remedies are used because they can 
improve the symptoms of  gastrointestinal diseases, such 
as dyspepsia, nausea, vomiting, and abdominal distension. 
Elenoside obtained from J. hyssopifolia could be used to treat 
these symptoms of  gastrointestinal diseases. It produced an 
increase in the catharsis index or number of  humid boluses; 
an enhancement of  the water volume of  boluses; and an 
increase in the distance traveled by the charcoal suspension. 
In addition, codeine phosphate totally antagonized its 
prokinetic action; in isolated rat duodenum, jejunum, and 
ileum, elenoside elicited a decrease in contraction force 
followed by an increase; and elenoside caused a decrease 
in intestinal frequency in duodenum and ileum, but not in 
jejunum.
In conclusion, elenoside in the gastrointestinal tract 
exhibits activities similar to that of  purgative and prokinetics 
drugs. Elenoside could be an alternative to cisapride in the 
treatment of  gastrointestinal diseases as well as a preventive 
of  the undesirable gastrointestinal effects produced by 
opioids used for mild to moderate pain.
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